Technoglitch
Core Member
The Punjab Medical Council has sent show cause notices to 10 doctors for receiving funds from pharmaceutical and allied healthcare companies. By accepting funds directly from these sources, the doctors have allegedly violated the Medical Council of India’s code of ethics, notes an October 27 news item in journalThe BMJ.
The Punjab Medical Council’s president, G.S. Grewal told the journal that the 10 doctors had received funds from drug companies through their personal bank accounts, thus violating the national rules. According to the rules, doctors cannot accept funds directly from drug companies, and any payments for any services rendered by them should be routed through their institutions.
The doctors are required to respond to the show cause notice by Wednesday, The BMJ notes. Proceedings against these doctors, which may include even suspension of their licenses, will be initiated if the council is unsatisfied with their responses.
According to the journal, 21 companies have been named in the show cause notice. These include foreign pharmaceutical companies Merck Limited, MSD Pharmaceuticals Private Limited, Sanofi India Limited, Bayer Zydus Pharma, and Novartis Healthcare Private Limited. The Indian-based companies in the list are Glenmark Pharmaceuticals, Ranbaxy Laboratories (now a part of Sun Pharmaceuticals), Intas Pharmaceuticals, Eris Life Sciences, and Lupin. The notice also named three cord blood banking companies and two insurance third party administrators.
Of the companies The BMJ had contacted, nine responded to the allegations. While Bayer Zydus Pharma and Glenmark Pharmaceuticals “confirmed that they had made the payments” to the doctors, they have insisted that their “actions did not violate the MCI's code of ethics.”
Show cause notices sent to 10 Indian doctors for receiving payment from drug companies - The Hindu
The Punjab Medical Council’s president, G.S. Grewal told the journal that the 10 doctors had received funds from drug companies through their personal bank accounts, thus violating the national rules. According to the rules, doctors cannot accept funds directly from drug companies, and any payments for any services rendered by them should be routed through their institutions.
The doctors are required to respond to the show cause notice by Wednesday, The BMJ notes. Proceedings against these doctors, which may include even suspension of their licenses, will be initiated if the council is unsatisfied with their responses.
According to the journal, 21 companies have been named in the show cause notice. These include foreign pharmaceutical companies Merck Limited, MSD Pharmaceuticals Private Limited, Sanofi India Limited, Bayer Zydus Pharma, and Novartis Healthcare Private Limited. The Indian-based companies in the list are Glenmark Pharmaceuticals, Ranbaxy Laboratories (now a part of Sun Pharmaceuticals), Intas Pharmaceuticals, Eris Life Sciences, and Lupin. The notice also named three cord blood banking companies and two insurance third party administrators.
Of the companies The BMJ had contacted, nine responded to the allegations. While Bayer Zydus Pharma and Glenmark Pharmaceuticals “confirmed that they had made the payments” to the doctors, they have insisted that their “actions did not violate the MCI's code of ethics.”
Show cause notices sent to 10 Indian doctors for receiving payment from drug companies - The Hindu
